JGJessy Goupeyou-Youmsi

Jessy Goupeyou-Youmsi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jessy Goupeyou-Youmsi has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mpox severity and mortality in the DRC: a systematic review and meta-analysis (1970–2024)

    by Fabrice Zobel Lekeumo Cheuyem, Armel Zemsi, Jonathan Hangi Ndungo, Chabeja Achangwa, Davy Roméo Takpando-Le-Grand, Jessy Goupeyou-Youmsi, Solange Dabou, Mohamadou Adama, Ariane Nouko, Marie Angèle Mbang, et al.

    Background: Mpox, caused by the Mpox virus, is a zoonotic disease historically endemic in Central and West Africa. Despite the Democratic Republic of Congo (DRC) carrying the highest Mpox burden, the literature lacks comprehensive data on long-term trends and geographic disparities inMpox% disease severity and mortality, highlighting a significant research gap. Understanding severity and mortality trends is critical for global control efforts. Methods: This systematic review and meta-analysis followed PRISMA guidelines to synthesize evidence on Mpox severity and mortality in the DRC from 1970 to 2024. We searched PubMed, ScienceDirect, Scopus, Web of Science. Random-effects models addressed high heterogeneity, and subgroup analyses examined temporal trends, regional differences, and healthcare settings. Meta-regression explored sources of heterogeneity for both severity and case fatality rate, adjusting for study year, region, and setting. Results: We included a total of 19 study reports. The pooled severity rate among 3,280 confirmed cases was 39.47% (95% confidence interval [CI] 29.11–50.86). Case fatality rates (CFRs) were 1.70% (95% CI 0.72–3.95) among 3152 suspected cases and 2.46% (95% CI 0.65–8.85) for 2239 confirmed cases. Meta-regression revealed that study year, region and setting were significant sources of heterogeneity of case fatality rates among confirmed mpox cases. Conclusion: Mpox continues to impose a substantial burden in the DRC, with a high severity and moderate mortality rates. Targeted interventions, including vaccination in high-risk areas, community education, and healthcare system strengthening are warranted.

  • Open Access

    Prevalence of high-risk human papillomavirus genotypes and associated HIV co-infection in Cameroon: a systematic review and meta-analysis

    by Fabrice Zobel Lekeumo Cheuyem, Chabeja Achangwa, Lionel Berthold Keubou Boukeng, Rick Tchamani, Alapa Junior Nkwate Chefor, Jessy Goupeyou-Youmsi, Edmond Martial Lemaire Bodo

    High-risk human papillomavirus (HR HPV) infection is the primary cause of cervical cancer, a leading cause of cancer mortality among women in sub-Saharan A

  • Contribution des anophèles à la transmission de Plasmodium falciparum et de Plasmodium vivax à Madagascar. Mise en place d'une plateforme expérimentale pour l'étude de leur compétence vectorielle

    by Jessy MarlèNE Goupeyou Youmsi

    Le paludisme demeure un problème de santé majeur en Afrique subsaharienne. Le nombre limité d'antipaludiques, l’apparition de résistances et l’absence d’un vaccin efficace, font de la lutte anti-vectorielle (LAV) la principale stratégie préventive de cette maladie. Les méthodes actuelles de LAV visant à limiter ou à interrompre le développement du parasite chez le moustique vecteur, il est donc nécessaire d’améliorer notre compréhension des interactions entre le vecteur Anopheles, son environnement et le parasite Plasmodium. A Madagascar, Anopheles gambiae s.l. et Anopheles funestus sont les vecteurs majeurs de Plasmodium falciparum et de Plasmodium vivax. Anopheles mascarensis, espèce endémique, peut également être un vecteur important. Dans ce contexte, l’objectif premier de ma thèse a été d’approfondir les connaissances sur An. mascarensis à travers une revue. Les données collectées plaident davantage qu’An. mascarensis est un complexe d'espèces et permettent de poser les bases pour une analyse moléculaire ciblée. En parallèle, j’ai contribué à la mise en place de la première plateforme expérimentale de Madagascar pour infecter des anophèles par P. falciparum et P. vivax, afin d’évaluer leur compétence vectorielle. Enfin, en associant entomologie et immuno-parasitologie, nous avons analysé la contribution des vecteurs à la transmission du paludisme dans deux villages adjacents. L’ensemble des travaux réalisés durant de ma thèse contribue à une meilleure connaissance de la diversité de la transmission du paludisme à Madagascar. De plus, la mise en place de la plateforme expérimentale d’infection permettra l’analyse de la compétence des populations d’anophèles vecteurs.

  • Open Access

    Mpox varicella-zoster virus coinfection in the Democratic Republic of Congo: a systematic review and meta-analysis

    by Fabrice Zobel Lekeumo Cheuyem, Constantine Tanywe Asahngwa, William Ndjidda Bakari, Chabeja Achangwa, Jessy Goupeyou-Youmsi, Brian Ngongheh Ajong, Claude Axel Minkandi, Solange Dabou, Mohamadou Adama, Jude Tsafack Zefack, et al.

    Introduction: Monkeypox (Mpox) is an endemic disease in the Democratic Republic of Congo (DRC). After five decades of outbreaks, gaps still remain in understanding clinical patterns and coinfections with varicella-zoster virus (VZV) and human immunodeficiency virus (HIV) in this high-burden setting. This systematic review and meta-analysis were conducted to synthesize data on Mpox clinical presentation and coinfection trends in the Democratic Republic of the Congo. Estimating the burden of VZV and HIV coinfections will help informing decision maker during the fight against this outbreak. Methods: This study was conducted by systematically extracting data from online databases including PubMed, ScienceDirect, and Google Scholar. The pooled estimate VZV and HIV coinfection rates were calculated using fixed and random-effects models. Subgroup analyses were performed by time period, region, study design, setting, and participant characteristics. Results Among a total of 1,841 confirmed Mpox cases, VZV coinfection was 9.69% (95% CI: 1.33–18.06; n = 8), with higher rates in Kivu (33.33%) compared to Equateur (11.10%). The VZV pooled prevalence rate among 64,131 suspected Mpox cases was 16.73% (95% CI: 5.36-28.10; n = 8), with I2 = 99.4% (p ˂ 0.001). The pooled estimate of HIV coinfection rate was low (0.52%, 95% CI: 0.18–0.87) at national level but elevated in South Kivu (1.64%). Among confirmed cases, rash (99.97%), painful lesions (78.17%), and Malaise (77.14%) were the main clinical presentation and this highlights their diagnostic importance in the case definition. A similar clinical pattern of Mpox was observed among suspected cases, were almost all recorded cases reported rash (99.43%) and fever (98.91%). Heterogeneity was high (I² > 90%) for most study outcomes. Conclusion: The substantial VZV coinfection prevalence and distinct regional HIV patterns highlight critical gaps in syndromic surveillance and the urgent need for integrated diagnostic strategies. This review confirms that Mpox in the DRC presents with near-universal rash, underlining their centrality to case definitions. These findings provide essential evidence for strengthening frontline detection and tailored outbreak response in endemic zones.


  • Open Access

    Prevalence of high-risk human papillomavirus genotypes and associated HIV co-infection in Cameroon: a systematic review and meta-analysis

    by Fabrice Zobel Lekeumo Cheuyem, Chabeja Achangwa, Lionel Berthold Keubou Boukeng, Rick Tchamani, Alapa Junior Nkwate Chefor, Jessy Goupeyou-Youmsi, Edmond Martial Lemaire Bodo

    Background: High-risk human papillomavirus (HR-HPV) infection is the necessary cause of cervical cancer, a leading cause of cancer mortality among women in sub-Saharan Africa. In Cameroon, there is a gap in synthetized evidence on HR-HPV epidemiology, limiting data-driven prevention strategies. This study provides the first comprehensive national synthesis of HR-HPV prevalence, genotype distribution, and HIV co-infection among HPV-infected individuals. Methods: A systematic review and meta-analysis were conducted following PRISMA guidelines and registered in PROSPERO (CRD420261282094). We systematically searched PubMed, Scopus, Web of Science, Embase, Cochrane Library, AJOL and local online publishers. Studies reporting the prevalence of HR-HPV among sexually active individuals were included. Pooled prevalence estimates were calculated using random-effects meta-analysis. Heterogeneity was assessed with I² statistics and explored through subgroup analyses. The methodological quality of included studies was evaluated using the Joanna Briggs Institute (JBI) critical appraisal tools. Results: A total of 33 studies including 18,798 participants were included in this analysis. The overall pooled prevalence of HR-HPV was 28.95% (95% CI: 19.74–40.30; 33 studies; n = 18,798; I 2 = 98.7%), with a notable decline from 53.34% before 2014 to 21.43% in 2021–2023. Prevalence varied substantially across populations, being highest among women with precancerous or cancerous lesions (90.69%; 95% CI: 78.48–96.30) and female sex workers (62.10%; 95% CI: 58.08–66.00) compared to women from the general population (21.09%; 95% CI: 15.16–28.55). Among HPV-positive women, HIV co-infection prevalence was 26.17% (95% CI: 13.48–44.65, 19 studies; n = 3,589; I 2 = 97.9%), with higher rates in hospital-based studies (34.57%) compared to community-based studies (9.18%). Predominant HR-HPV genotypes included HPV16 (28.7%), HPV52 (23.6%), HPV6 6 (22.9%), HPV33 (22.8%), and HPV18 (20.2%). The pooled prevalence of abnormal cervical lesions among HPV-positive women was 35.15% (95% CI: 20.21–53.70; 12 studies; n = 2,186; I 2 = 95.2%), comprising low-grade lesions (34.4%) and high-grade lesions (19.1%). Conclusions: High-risk human papillomavirus infection remains highly prevalent in Cameroon despite encouraging temporal declines. The substantial burden of HIV co-infection and circulation of multiple oncogenic genotypes underscore the need for integrated HPV–HIV prevention strategies, expanded screening, and consideration of broader-coverage vaccines to accelerate progress toward cervical cancer elimination targets.

  • Open Access

    Anopheles mascarensis, a Malaria Vector Endemic to Madagascar and the Comoros Archipelago: A Review

    by Jessy Goupeyou-Youmsi, Luciano M. Tantely, Tsarasoa M. Andrianinarivomanana, Romain Girod, Catherine Bourgouin

    : Anopheles mascarensis ( An. mascarensis ; De Meillon, 1947) is a mosquito species endemic to Madagascar and the Comoros Archipelago. In the past, it was confused with Anopheles marshalli (Theobald, 1929), a continental African species that does not exist in Madagascar. Malaria transmission is highly heterogeneous in Madagascar. Principal and secondary mosquito vectors, as well as malaria parasite species, may vary from one region to another. Anopheles mascarensis has been identified as the main vector of malaria in the east and southeast of Madagascar, while it plays the role of a secondary vector in other Malagasy regions. Differences in behavior between An. mascarensis populations from the east coast and those from the Central Highlands of Madagascar suggest that An. mascarensis may be composed of sibling species. In the present review, unpublished data on the geographical distribution of An. mascarensis were assembled to update the previous distribution map published in 1966. In addition, published data on the biology of this mosquito, its geographical variants, and records of its role in malaria transmission were analyzed. The published data highlight a significant difference between populations from the east coast and those from the Central Highlands, revealing a possible gradient along different climatic and biogeographic regions of Madagascar. This analysis supports the idea that An. mascarensis may consist of a complex of sibling species. With advances in molecular tools, testing this hypothesis is increasingly within reach.


  • Open Access

    Mpox vaccine acceptance and uptake in Africa: a systematic review and meta-analysis (1970-2024)

    by Fabrice Zobel Lekeumo Cheuyem, Andreas Ateke Njoh, Chabeja Achangwa, Otfried Kistner, Rick Tchamani, Jessy Goupeyou-Youmsi, Davy Roméo Takpangdo-Legrand, Sory Kourouma, Mazou Ngou Temgoua

    Background: Mpox remains a significant public health threat in Africa, with recent outbreaks driven by newly emergent clades I and II. Vaccination is a critical intervention for outbreak control, yet evidence on vaccine acceptance and uptake across the continent has not been comprehensively synthesized. This study aimed to determine the pooled prevalence and determinants of mpox vaccine acceptance and uptake in Africa. Methods: We conducted a systematic review and meta-analysis following PRISMA guidelines, registered with PROSPERO (CRD420251126033). We searched PubMed, Scopus, Web of Science, CINAHL, ScienceDirect, and African Journals Online from 1970 to August 2025. Data were extracted using a standardized form, and quality was assessed with Joanna Briggs Institute tools. Pooled estimates were calculated using random-effects generalized linear mixed models with Probit-Logit transformation. Subgroup analyses and meta-regressions explored heterogeneity by region, population, setting, and time period. Results: Of 9,748 records screened, 35 studies were included. The overall mpox vaccine acceptance rate was 53.55% (95% CI: 46.16–60.79), with high heterogeneity (I 2 =98%). Central Africa showed moderate acceptance at 54.17% (95% CI: 20.82–84.16), Eastern Africa at 54.16% (95% CI: 42.43– 65.44), while Western Africa was lower at 50.11% (95% CI: 39.94–60.27). Acceptance was highest in Southern Africa (67.43%; 95% CI: 61.85–72.67). Healthcare workers’ acceptance was 51.63% (95% CI: 39.37–63.70) and medical students’ was 46.17% (95% CI: 38.53–54.01), both lower than the general population (62.46%; 95% CI: 52.25–71.66). Actual vaccine uptake was 20.94% (95% CI: 10.06–38.56), varying significantly by country, with the Democratic Republic of the Congo at 20.01% (95% CI: 7.45–43.75). A significant decline occurred after 2022 (pre-2022: 36.0% [95% CI: 19.74–56.26]; post-2022: 3.4% [95% CI: 0.56–17.96]). Key determinants of acceptance included higher mpox knowledge, trust in health authorities, prior vaccination history, and free vaccine access. Conclusion: There is a substantial gap between mpox vaccine acceptance and actual uptake in Africa, with a significant decline in coverage since 2022. Strategies to enhance vaccination must address both demand and supply challenges, including equitable distribution and integration into routine immunization systems. These findings underscore the need for context-specific, multi-level interventions to translate willingness into actual vaccine uptake.


  • Open Access

    Healthcare coverage and associated factors in Cameroon: analyses from a national survey

    by Fabrice Zobel Lekeumo Cheuyem, Constantine Tanywe Asahngwa, Solange Dabou, Brian Ngongheh Ajong, Guy Stéphane Nloga, Jessy Goupeyou-Youmsi, Ariane Nouko, Edwige Omona Guissana, Rick Tchamani, Ethel Ambo Eno, et al.

    Background Emergency medicine systems are vital for reducing mortality and disability, yet Cameroon faces significant healthcare access challenges, with only 0.6% of GDP allocated to public health and 70% of health expenditures paid out-of-pocket. This study assessed proportion of population benefiting from health coverage, patterns, and associated factors in Cameroon to inform policies aimed at achieving universal health coverage (UHC). Methods A nationally representative cross-sectional survey was conducted from February to March 2024, involving 1,200 adults selected via multistage random sampling. Data were collected through face-to-face interviews by national Afrobarometer team, and analyzed with R Statistics version 4.4.2. Logistic regression identified factors associated with medical coverage, adjusting for sociodemographic, economic, and occupational variables. Results A proportion of 7.9% (95% CI: 6.4–9.6) of respondents reported benefiting from a health coverage in 2024, with the lowest rates reported in the North, Adamawa, Centre, and North-West regions. Private health insurance was the most common (44.3%), followed by civil servant schemes (20.5%) and community-based insurance (15.9%). Unemployed individuals were twice as likely to lack coverage (aOR = 2.22, 95% CI: 1.42–3.51). Those with secondary education had twice the odds of being uninsured compared to tertiary-educated individuals (aOR = 2.00, 95% CI: 1.21–3.27). Insured individuals were more likely to use healthcare services (9.6%; p = 0.028), reported easier access to medical care (15.8%; p = 0.010), and expressed fewer concerns about healthcare access (23.4%; p < 0.001). Barriers among the uninsured included high costs (37.1%), lack of information (31.6%), complex registration processes (8.5%) and geographical constraints. Most of the community members reported being quite (51.1%) or very satisfied (23.9%) by the medical coverage they are benefiting from. Notably, 68% of respondents supported higher taxes to improve healthcare access. Conclusion Cameroon’s suboptimal medical coverage reflects systemic inequities tied to employment and education. Expanding employer-independent schemes, subsidizing premiums, and leveraging community-based models are critical to advancing UHC. Public willingness to contribute through taxes suggests political viability for systemic reforms.


  • Open Access

    Mpox vaccination coverage in the Democratic Republic of Congo: A systematic review and meta-analysis of uptake and acceptance (1970–2024)

    by Fabrice Zobel Lekeumo Cheuyem, Adidja Amani, Adamu Abubakar Umar, Chabeja Achangwa, Brian Ngongheh Ajong, Solange Dabou, Jessy Goupeyou-Youmsi, Guy Roger Pilo Ndibo, Rick Tchamani, Ethel Ambo Eno, et al.

    Background: The Democratic Republic of Congo (DRC) is recognized as the global epicenter of human Mpox. While vaccination is crucial for outbreak prevention, especially as the disease transitions from zoonotic spillover to sustained human-to-human transmission, comprehensive assessments of vaccination coverage trends across the country are notably absent from the literature. This systematic review and meta-analysis address this gap by providing the first pooled estimate of Mpox vaccine uptake and acceptance in the DRC over a 54-year period (1970-2024). Our study captures critical transitions, including the post-smallpox eradication era and recent global outbreaks, to identify temporal trends, geographic disparities in this high-risk setting. Methods: We conducted this review following PRISMA guidelines, systematically searching PubMed, Scopus, ScienceDirect, Web of Sciences, CINAHL, and Embase. Grey literature was also searched to ensure comprehensiveness. Using random-effects models, we calculated pooled estimates for vaccine uptake and acceptance rates, with prespecified subgroup analyses examining variations by: (1) period, (2) geographic region, and (3) type of participants. We quantified heterogeneity using I 2 statistics and conducted meta-regression to identify predictors of vaccination coverage heterogeneity. A p-value ⍰ 0.05 was considered statistically significant. Results: Our analysis revealed a pooled Mpox vaccine uptake of 20.01% (95% CI: 7.45–43.75) with high heterogeneity ( I 2 = 99.4%, p < 0.001), indicating substantial variability across studies. Vaccine acceptance was higher at 54.17% (95% CI: 20.82–84.16) with high heterogeneity ( I 2 = 97.6%, p < 0.001). Temporal analysis showed a significant decline from 32.30% (95% CI: 14.62–57.75) coverage during 1970–2000 to 1.36% (95% CI: 0.29–6.11) in 2020–2024. Geographic disparities existed, with the Northwest regions achieving 47.11% (95% CI: 13.46–83.61) coverage compared to 5.47% (95% CI: 0.56–37.32) in Eastern conflict-affected zones. Meta-regression identified no significant predictors of coverage heterogeneity. Conclusion: Despite moderate acceptance rates, actual Mpox vaccination uptake in the DRC remains critically low, with worsening coverage in recent years and substantial regional inequities. These findings underscore the urgent need for context-specific interventions to bridge the intention-action gap in this high-risk setting.

  • Open Access

    Mpox clinical features and varicella-zoster virus coinfection in the Democratic Republic of Congo: a systematic review and meta-analysis (1970–2024)

    by Fabrice Zobel Lekeumo Cheuyem, Constantine Tanywe Asahngwa, William Ndjidda Bakari, Chabeja Achangwa, Jessy Goupeyou-Youmsi, Brian Ngongheh Ajong, Claude Axel Minkandi, Mohamadou Adama, Jonathan Hangi Ndungo, Jude Tsafack Zefack, et al.

    Background: Monkeypox (Mpox) remains endemic in the Democratic Republic of Congo (DRC), with inc. Despite five decades of outbreaks, gaps persist in understanding clinical patterns and coinfections with varicella-zoster virus (VZV) and HIV in this high-burden setting. Methods: We conducted a systematic review and meta-analysis (1970–2024) of Mpox cases in the DRC, extracting data from PubMed, ScienceDirect, and Google Scholar. Pooled prevalence rates were calculated using fixed and random-effects models, with subgroup analyses by time period, region, setting, study design and participant characteristics. Results: Among 1,841 confirmed Mpox cases, VZV coinfection was 9.69% (95% CI: 1.33–18.06; n = 8), with higher rates in Kivu (33.33%) versus Equateur (11.10%). The VZV pooled prevalence rate among 64131 suspected Mpox cases was 16.73% (95% CI: 5.36-28.10; n = 8), with I 2 = 99.4% ( p □ 0.001). HIV coinfection was low (0.52%, 95% CI: 0.18–0.87) but elevated in South Kivu (1.64%). Among confirmed cases, rash (99.97%), painful lesions (78.17%), and Malaise (77.14%) dominated clinical presentation and underscored their diagnostic importance in the case definition. A similar clinical pattern of Mpox was observed among suspected cases, featuring a near-universal presentation of rash (99.43%) and fever (98.91%). Heterogeneity was high ( I 2 > 90% ) for most outcomes. Conclusion: Mpox in the DRC presents with consistent rash-centered symptomatology but high VZV coinfection rates complicate diagnosis. The low HIV coinfection suggests distinct transmission dynamics from global outbreaks. Findings underscore the need for integrated VZV/Mpox diagnostics and context-specific surveillance in endemic regions.